Frontiers Case report: Short-term eculizumab use in atypical HUS
Por um escritor misterioso
Descrição
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study, BMC Nephrology
Frontiers An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome
PDF) Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome
Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study - ScienceDirect
PDF) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses
The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review
PDF) First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient
PDF) Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease
Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future
PDF) Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature
Frontiers Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults
Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era
de
por adulto (o preço varia de acordo com o tamanho do grupo)
